BiotechTube

Eculizumab + Ravulizumab + BCX9930

Phase 2Terminated
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Trial Timeline

Dec 6, 2021 → Sep 14, 2023

NCT ID
NCT05116774

About Eculizumab + Ravulizumab + BCX9930

Eculizumab + Ravulizumab + BCX9930 is a phase 2 stage product being developed by BioCryst Pharmaceuticals for Paroxysmal Nocturnal Hemoglobinuria (PNH). The current trial status is terminated. This product is registered under clinical trial identifier NCT05116774. Target conditions include Paroxysmal Nocturnal Hemoglobinuria (PNH).

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05116774Phase 2Terminated

Competing Products

20 competing products in Paroxysmal Nocturnal Hemoglobinuria (PNH)

See all competitors
ProductCompanyStageHype Score
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
Crovalimab + PlaceboChugai PharmaceuticalPhase 1/2
41
Crovalimab + EculizumabChugai PharmaceuticalPhase 3
77
RavulizumabAstraZenecaPre-clinical
23
EculizumabAstraZenecaPhase 3
77
DanicopanAstraZenecaPhase 3
77
LNP023NovartisPre-clinical
23
Iptacopan (LNP023)NovartisPhase 3
77
iptacopanNovartisPhase 2
52
LNP023NovartisPhase 2
52
IptacopanNovartisPre-clinical
23
IptacopanNovartisPhase 3
77
LNP023 + Eculizumab + RavulizumabNovartisPhase 3
77
LNP023NovartisPhase 3
77
LFG316 + LNP023NovartisPhase 2
52
IptacopanNovartisPhase 3
77
CrovalimabRochePhase 3
77
ABP 959 + EculizumabAmgenPhase 3
76
PegcetacoplanSwedish Orphan BiovitrumPre-clinical
22
BMS-919373 + Placebo (Matching with BMS-919373)Bristol Myers SquibbPhase 2
51

Other Products from BioCryst Pharmaceuticals

Peramivir + Placebo ComparatorPhase 3
72
Peramivir + OseltamivirPhase 3
72
PeramivirPhase 3
72
avoralstatPhase 3
72
Peramivir 150mg + Peramivir 300mgPhase 3
72